Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway.

This study explored the effect of ginsenoside Rg3 on DNA repair and VRK1/P53BP1 signaling pathway. Ginsenoside Rg3 treatment significantly decreased the incidence and invasionin a mouse model of lung cancer induced by urethane. The results of cell survival assay and single cell gel electrophoresis showed that ginsenoside Rg3 protected lung adenocarcinoma cells from DNA damage as well as inhibited the proliferation of tumor cells. Ginsenoside Rg3 increased the mRNA and protein expression of VRK1 in NSCLC cells as measured by RT-qPCR and western blot, respectively. These findings suggests that ginsenoside Rg3 regulates VRK1 signaling. Immunofluorescence assays showed that P53BP1 and VRK1 protein level increased, and the VRK1 protein translocated between the nuclei and cytoplasm. Finally, this conclusion was confirmed by the reverse validation in VRK1-knockdown cells. Taken together, these results show that ginsenoside Rg3 upregulate VRK1 expression and P53BP1 foci formation in response to DNA damage thereby inhibiting the tumorigenesis and viability of cancer cells. These findings reveal the role of Rg3 in lung cancer and provides therapeutic targets for developing new drugs in the prevention and treatment of lung cancer. PMID: 31629252 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research

Related Links:

This study was designed to evaluate the efficacy of different generations of EGFR TKI therapy in ASC patients with sensitiveEGFR mutations.MethodsPatients with non-small cell lung cancer (NSCLC) diagnosed at the Shanghai Chest Hospital between January 2010 and December 2016 were retrospectively reviewed.ResultsA total of 10,037 NSCLC patients tested forEGFR mutations were screened, with primary ASC accounting for 1.4% (139/10,037). PositiveEGFR mutations were found in 51.1% (71/139) of ASC patients, including 67 sensitive mutations (19del or 21L858R) and four uncommon mutations (19del  + 20T790M, 21L858R&thin...
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
We set out to investigate whether transcriptome-based molecular subtypes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are predictive of response to PD-1 blockade.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Authors: Jiang W, He J, Lv B, Xi X, He G, He J Abstract Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. Lung adenocarcinoma is the main tumor type of NSCLC. Recent advances in the molecular characterization and personalized therapies have improved NSCLC patient prognosis. Previous studies showed that protein tyrosine kinase 7 (PTK7) plays an important role in human cancers. However, the role of PTK7 has not been investigated. PTK7 expression was assessed by immunohistochemistry in 95 patients with lung adenocarcinoma. Correlations of PTK7 expression levels with clinicopath...
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research
ConclusionOur study revealed that concurrent genomic alterations can further stratify KRAS ‐mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype amongKRAS‐mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
SUMMARY AIM To examine the relationship between treatment response and hypoxia-inducible factor-1 alpha (HIF-1 α ) levels in patients with locally advanced non-small cell lung cancer (NSCLC) who received chemoradiotherapy (CRT). METHODS Eighty patients with NSCLC were included in the study and treated at Acibadem Mehmet Ali Ayd ı nlar University Medical Faculty. HIF-1 α levels were measured before and after CRT by the enzyme-linked immunosorbent assay (ELISA) method. RESULTS Patients ’ stages were as follows; stage IIIA (65%) and stage IIIB (35%). Squamous histology was 45%, adenocarcinoma was 44%, and o...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
AbstractBackgroundThere are several studies comparing the difference between adenocarcinoma (AC) and squamous cell carcinoma (SqCC) of lung cancer. However, seldom studies compare the different overall survival (OS) between AC and SqCC at same clinical or pathological stage. The aim of the study was to investigate the 5-year OS between AC and SqCC groups.MethodsData were obtained from the Taiwan Society of Cancer Registry. There were 48,296 non-small cell lung cancer (NSCLC) patients analyzed between 2009 and 2014 in this retrospective study. We analyzed both the AC and SqCC groups by age, gender, smoking status, Charlson ...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Contributors : P Vijayanand ; C H Ottensmeier ; Tilman Sanchez-Elsner ; Eva M Garrido-MartinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTumour Associated Macrophages (TAMs) are considered as functionally inactive or re-shaped by the tumour into a pro-tumour M2 phenotype. There is lack of transcriptomic data of TAMs purified from human cancers. We performed transcriptomic analyses on TAMs isolated from human NSCLC in comparison with matched tumour-free lung tissue macrophages from the same patients. TAMs are essentially M2 activated, but in some patients TAMs also exhibit a strong ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Conclusions: Our study elucidate the prognostic impact of tissue AXL expression and the presence of CTCs after surgery in adenocarcinoma patients. Tissue AXL expression and CTC EMT activation could potentially represent biomarkers for the stratification of ADC patients that might benefit from new adjuvant therapies.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionThese data suggest that the mutational profiles among the predominant histological subtypes were very distinct, which provided a reliable tool to improve treatment decisions.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Despite years of research, KRAS mutant non-small cell lung cancer (NSCLC) remains a major unmet clinical need. KRAS mutations, the second most common genomic alteration in human cancer after TP53 mutations, occur in 25-30 percent of lung adenocarcinomas [1,2]. High affinity binding of KRAS to its GTP substrate has hindered the development of therapeutic agents that directly inhibit KRAS. Only recently have KRAS-specific inhibitors have been developed [3,4]. Among them, direct, covalent KRASG12C inhibitors have demonstrated encouraging efficacy and appear well tolerated [5,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Gastroschisis Repair | Ginseng | Lung Cancer | Non-Small Cell Lung Cancer | Study